Anti-Rheumatic Drugs - LATAM
LATAM- Revenue in the Anti-Rheumatic Drugs market is projected to reach US$1.18bn in 2024.
- Revenue is expected to show an annual growth rate (CAGR 2024-2028) of 0.83%, resulting in a market volume of US$1.22bn by 2028.
- In global comparison, most revenue will be generated United States (US$34.70bn in 2024).
- Key regions:
- Germany,
- United States,
- India,
- Japan,
- United Kingdom
Definition:
The market Anti-Rheumatic Drugs includes medication for the treatment of the inflammatory disease rheumatism. Due to the high prevalence of rheumatism and the large size of the market, this section of immune diseases is treated as a separate market. Both steroidal and non-steroidal anti-rheumatics are included. Disease-modifying rheumatic drugs (DMARDs), such as tumor necrosis factor inhibitors (a type of biologic DMARD), are particularly important in terms of commerciality.
Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).
Company examples: AbbVie, Johnson & Johnson, Pfizer, Amgen, Roche
In-Scope
- Drugs to treat rheumatism
- Steroidal (corticosteroids) and non-steroidal anti-rheumatics
- Disease-modifying antirheumatic drugs (DMARDs)
- Tumor necrosis factor (TNF) inhibitors
Out-Of-Scope
- Drugs to treat other autoimmune diseases (such as multiple sclerosis or psoriasis)
- Analgetics for general use (such as paracetamol)
- Treatment of osteoarthritis
